Articles On Optiscan Imaging (ASX:OIL)

Optiscan signs collaborative research agreement with the University of Minnesota College of Veterinary Medicine It’s a significant milestone in Optiscan’s growth strategy to enter lucrative veterinary market Initial focus will be on cancer...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

  Optiscan enters deal with Monash University to progress project of developing a scope-agnostic GI flexible endomicroscope Optiscan will collaborate with Monash University to develop the project’s next-gen AI technology The project has r...

Telix Pharmaceuticals will benefit from ongoing favourable US pay arrangements for high-value radiopharmaceutical diagnostics Optiscan teams with Monash University to develop a next-gen endomicroscope – and AI is involved BOD Australia inv...

World Health Organsiation projects a shortfall of 10 million health workers by 2030 HeraMED’s platform helps healthcare providers manage maternity patients remotely Optiscan platform could address shortage of pathologists in Australia and...

Stockhead’s Sarah Hughan sits down with Optiscan’s (ASX:OIL) CEO and managing director Dr Camile Farah to get the short end of the long story on the company’s latest news. The medical imaging’s business development team has been busy in the...

Optiscan’s confocal laser endomicroscopy enables real-time imaging of tissue and avoids the need for painful biopsies The company says 25% to 30% of cases require second surgery because the clinician has missed excising part of the tumour...

New technologies are transforming healthcare and challenging traditional medical practices Optiscan’s technology is about bringing pathologists and surgeons closer together in real time for faster diagnosis Singular Health’s 3Dicom product...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX flattish on Monday, with utilities and gold stocks leading A2 Milk’s shares plummeted 20pc amid challenges in China Westpac and Suncorp saw gains of nearly 2pc after results release   Trading on the ASX was relatively quiet on Monday...

  Optiscan inks deal with the University of Minnesota College of Veterinary Medicine Deal will develop clinical data for Optiscan’s digital confocal laser endomicroscopic imaging system for use in veterinary medicine Data from clinical stu...

Control Bionics to gain US$4,300 reimbursement for its NeuroNode device Noxopharm begins a trial for SOF-SKN, targeting lupus, with results due in 2025 HitIQ signs a two-year deal with Westfield Sports High School   Control Bionics to be...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Several ASX healthcare companies are proudly manufacturing products in Australia  Polynovo, Optiscan and Trajan Group all have manufacturing facilities in Melbourne Orthocell says government funding can boost manufacturing capabilities of...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Optiscan’s (ASX:OIL) major milestone in developing its cloud-based telepathology platform, with the comple...

Commercial-stage medical technology company Optiscan Imaging (ASX: OIL) has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies. The platform is believed to represent a...

Optiscan to showcase its innovative cloud-based telepathology platform dorsaVi seals crucial contracts across different sectors    Optiscan completes beta testing of breakthrough technology Optiscan Imaging (ASX:OIL), in partnership with...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to CEO + Managing Director at Optiscan (ASX:OIL) Dr Camile Farah, who is also a trained clinic...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

S&P/ASX 200 rose 1% in June with large caps leading gains with mid, small and emerging companies lagging S&P/ASX 200 financials and consumer staples were the top performers in June with materials the biggest laggard Urea fertiliser...

The ASX200 closed the day in the red, down 0.3%. It was a rough day for the Energy sector, falling 1.6%, with Materials down 0.9%. The Financial and Staples sectors were the only ones that pushed into the green, both up around 0.2%. I...

Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang   Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact...

Optiscan (ASX: OIL) has unveiled InVue,  a new microscopic medical imaging device, designed to enable precision surgery by putting real-time digital pathology access directly into the hands of surgeons. Designed and manufactured in Melbo...

Optiscan unveils the InVue next-gen microscopic medical imaging device for precision surgery InVue broadens Optiscan’s product portfolio into the surgical application market, a significant step forward in achieving its strategic objectives...

Optiscan Imaging (ASX: OIL) has revealed the InVue microscopic medical imaging device, designed to benefit the surgical market by providing real-time digital pathology access to surgeons. The Australian-made device was developed in partners...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Optiscan enters know-how agreement with world-renowned Mayo Clinic for major pathology breakthrough Two organisations working to develop a digital confocal laser endomicroscopic imaging system for robotic surgery Optiscan has become a lead...

The ASX200 closed fractionally up by 0.01 of a per cent. Energy had a rough run – slipping around a per cent – while consumer discretionary and healthcare climbed around half a per cent. In the green West Australian gold producer R...

ASX flat on Monday,  ahead of Federal Budget Tuesday night Oil weakness drags Energy sector lower Chinese shares slump on new US tariffs   After advancing 1.5% last week, the ASX200 fell flat on Monday – greenish by 0.01% – dragged down m...

Optiscan Imaging (ASX:OIL) is set to partner with Mayo Clinic to develop a cutting-edge digital confocal laser endomicroscopic imaging system specifically designed for use in robotic surgeries. The collaboration brings together Optiscan...

Optiscan signs deal with world-renowned Mayo Clinic AdAlta designates Cell Therapies as its manufacturing partner Ecofibre jumps after entering sell and leaseback agreement in US   Optiscan signs deal with Mayo Clinic Optiscan Imaging (AS...

ASX closed higher on Friday as energy stocks lifted Oil prices up as Middle East conflict intensifies US to impose new tariffs on China – covering electric vehicles, batteries, and solar cells    Aussie shares were on the up on Friday, c...

Optiscan Imaging says its latest financial results are just the tip of the iceberg, confident a stronger staff presence in the US health market will soon reap the rewards for its revolutionary medical devices.

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Several ASX medtech companies have upcoming catalysts in 2024 as they look to transform healthcare  Imricor preparing to treat its first ventricular tachycardia patient this quarter  Optiscan on schedule for launch of breast surgical devic...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. William J. O’Neil, the founder of Investor’s...

Medical device manufacturer Optiscan Imaging has expanded its U.S push, opening an office in the biotech hub of Minnesota with two well-credentialed hires.

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Special Report: Optiscan is beefing up its presence in the US as it works toward securing US regulatory approvals for its confocal endomicroscopic imaging technologies.  Optiscan (ASX:OIL) has started to ramp up its presence in the US after...

Optiscan Imaging (ASX:OIL) has announced the establishment of its US Regional Office in Rochester, Minnesota, and the appointment of two US-based heads of clinical and regulatory affairs.

Optiscan Imaging’s ongoing studies aimed at producing revolutionary medical imaging devices have received a timely financial boost through a $672,320 research and development tax rebate from the ATO.

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...